Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.
Tag Archive for: cancer
Researchers uncover a potential strategy to target and inhibit the androgen receptor in aggressive prostate cancer by exploiting protein droplets.
AbbVie buys ImmunoGen in US$10 billion deal, gains access to ADC for ovarian cancer. The ADC space gets hotter and hotter.
The Swedish start-up AAX Biotech welcomed Maria Lisa Knudsen as its new Managing Director at the end of September.
Pierre Fabre Laboratories, a leading French medical and beauty care company and Vernalis (R&D) Ltd, a fully owned subsidiary of HitGen Inc. and a specialist in drug discovery announce a long-term partnership for oncology drug discovery.
French pharma company Pierre Fabre Laboratories has baged Vertical Bio to push development of the companys NSCLC candidate.
C
Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting Claudin-1 (CLDN1). The molecule is significantly involved in the tight junction between cells. Now the company closed a three digit million Seriec C round.
BioNTech has entered the ADC field with an exclusive license and collaboration agreement with Chinas DualityBio Ltd for two antibody-drug conjugate (ADC) assets.
The charity Cancer Research UK and UCB SA collaborate on the development of two potential cures for cancer.
SOTIO Biotech a.s. has exercised its first of five exclusive, target-specific options for antibody-drug conjugate (ADC) SOT106 under its agreement with LegoChem Biosciences Inc.